CASC3 and neoplasm: As shown in Fig 5C, while the JBI-097 as a single agent showed TGI of 23% at 12.5 mg/Kg dose, the combination of JBI-097 with BTZ led to a more potent reduction in tumor volume, with a TGI of 82%, similarly, JBI-097 showed a TGI of 60% in combination with pomalidomide.